{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:02:18Z","timestamp":1790715738590,"version":"4.1.0"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"DOI":"10.1186\/s43046-026-00415-1","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:45:12Z","timestamp":1790667912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation CAR-T cell therapy against cancer: precision engineering, programmable immunity, and emerging clinical frontiers"],"prefix":"10.1186","volume":"38","author":[{"given":"Faizan-e-","family":"Mustaffa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahbaz","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3963-927X","authenticated-orcid":false,"given":"Muhammad","family":"Junaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"3","key":"415_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"1","key":"415_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang C-H, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target therapy. 2025;10(1):227.","journal-title":"Signal Transduct Target therapy"},{"issue":"1","key":"415_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","volume":"24","author":"M Zhang","year":"2025","unstructured":"Zhang M, et al Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer. 2025;24(1):136. https:\/\/doi.org\/10.1186\/s12943-025-02305-x.","journal-title":"Mol Cancer"},{"issue":"1","key":"415_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target therapy. 2025;10(1):210.","journal-title":"Signal Transduct Target therapy"},{"issue":"3","key":"415_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41577-024-01093-7","volume":"25","author":"S Minguet","year":"2025","unstructured":"Minguet S, Maus MV, Schamel WW. From TCR fundamental research to innovative chimeric antigen receptor design. Nat Rev Immunol. 2025;25(3):212\u201324.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"415_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","volume":"12","author":"RM Young","year":"2022","unstructured":"Young RM, Engel NW, Uslu U, Wellhausen N, June CH. Next-generation CAR T-cell therapies. Cancer Discov. 2022;12(7):1625\u201333.","journal-title":"Cancer Discov"},{"issue":"1","key":"415_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","volume":"24","author":"Y Lu","year":"2025","unstructured":"Lu Y, Zhao F. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol Cancer. 2025;24(1):126.","journal-title":"Mol Cancer"},{"key":"415_CR8","doi-asserted-by":"publisher","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. eBioMedicine. 2022;77. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103941.","DOI":"10.1016\/j.ebiom.2022.103941"},{"issue":"1","key":"415_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X, et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer. 2024;23(1):175.","journal-title":"Mol Cancer"},{"issue":"7","key":"415_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Advances in the mechanisms and management of CAR T-cell toxicities. Nat Rev Clin Oncol. 2024;21(7):501.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"415_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","volume":"23","author":"E Pinto","year":"2025","unstructured":"Pinto E, et al. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. J translational Med. 2025;23(1):10.","journal-title":"J translational Med"},{"issue":"1","key":"415_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-023-01680-5","volume":"9","author":"F Teng","year":"2024","unstructured":"Teng F, Cui T, Zhou L, Gao Q, Zhou Q, Li W Programmable synthetic receptors: the next-generation of cell and gene therapies. Signal Transduct Target Therapy. 2024;9(1):7. https:\/\/doi.org\/10.1038\/s41392-023-01680-5.","journal-title":"Signal Transduct Target Therapy"},{"issue":"5","key":"415_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s41423-024-01153-x","volume":"21","author":"B Zhu","year":"2024","unstructured":"Zhu B, et al. Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy. Cell Mol Immunol. 2024;21(5):436\u201347.","journal-title":"Cell Mol Immunol"},{"key":"415_CR14","doi-asserted-by":"publisher","first-page":"1698442","DOI":"10.3389\/fonc.2025.1698442","volume":"15","author":"JE Garcia-Robledo","year":"2026","unstructured":"Garcia-Robledo JE, et al. Engineering the next generation of CAR T-cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance. Front Oncol. 2026;15:1698442.","journal-title":"Front Oncol"},{"issue":"6","key":"415_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41580-023-00697-6","volume":"25","author":"L Villiger","year":"2024","unstructured":"Villiger L, Joung J, Koblan L, Weissman J, Abudayyeh OO, Gootenberg JS CRISPR technologies for genome, epigenome and transcriptome editing. Nat Rev Mol Cell Biol. 2024;25(6):464\u201387. https:\/\/doi.org\/10.1038\/s41580-023-00697-6.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"415_CR16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108. https:\/\/doi.org\/10.1038\/s41423-024-01207-0.","journal-title":"Cell Mol Immunol"},{"key":"415_CR17","doi-asserted-by":"publisher","first-page":"1457629","DOI":"10.3389\/fimmu.2024.1457629","volume":"15","author":"M Fang","year":"2024","unstructured":"Fang M, Allen A, Luo C, Finn JD. Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy. Front Immunol. 2024;15:1457629.","journal-title":"Front Immunol"},{"issue":"5","key":"415_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short L, Holt RA, Cullis PR, Evgin L. Direct in vivo CAR T cell engineering. Trends Pharmacol Sci. 2024;45(5):406\u201318.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"415_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12951-024-02630-1","volume":"22","author":"MB Khawar","year":"2024","unstructured":"Khawar MB, Afzal A, Si Y, Sun H Steering the course of CAR T cell therapy with lipid nanoparticles. J Nanobiotechnol. 2024;22(1):380. https:\/\/doi.org\/10.1186\/s12951-024-02630-1.","journal-title":"J Nanobiotechnol"},{"issue":"4","key":"415_CR20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh M, Mansilla-Soto J, Rivi\u00e8re I, Sadelain M. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 2023;13(4):829\u201343.","journal-title":"Cancer Discov"},{"key":"415_CR21","doi-asserted-by":"publisher","first-page":"1519671","DOI":"10.3389\/fimmu.2024.1519671","volume":"15","author":"Y Kong","year":"2025","unstructured":"Kong Y, Li J, Zhao X, Wu Y, Chen L. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Front Immunol. 2025;15:1519671.","journal-title":"Front Immunol"},{"key":"415_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/bs.apcsb.2024.02.003","volume":"140","author":"S Dey","year":"2024","unstructured":"Dey S, Devender M, Rani S, Pandey RK. Recent advances in CAR T-cell engineering using synthetic biology: paving the way for next-generation cancer treatment. Adv Protein Chem Struct Biology. 2024;140:91\u2013156.","journal-title":"Adv Protein Chem Struct Biology"},{"key":"415_CR23","doi-asserted-by":"publisher","first-page":"1489827","DOI":"10.3389\/fimmu.2024.1489827","volume":"15","author":"SH Khan","year":"2025","unstructured":"Khan SH, Choi Y, Veena M, Lee JK, Shin DS. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors. Front Immunol. 2025;15:1489827.","journal-title":"Front Immunol"},{"key":"415_CR24","doi-asserted-by":"publisher","first-page":"1335424","DOI":"10.3389\/fimmu.2024.1335424","volume":"15","author":"S Smirnov","year":"2024","unstructured":"Smirnov S, Mateikovich P, Samochernykh K, Shlyakhto E. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic. Front Immunol. 2024;15:1335424.","journal-title":"Front Immunol"},{"issue":"1","key":"415_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/ejh.14076","volume":"112","author":"N Khan","year":"2024","unstructured":"Khan N, Asija S, Pendhari J, Purwar R. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for? Eur J Haematol. 2024;112(1):6\u201318.","journal-title":"Eur J Haematol"},{"key":"415_CR26","doi-asserted-by":"publisher","unstructured":"Smirnov S, Mateikovich P, Samochernykh K, Shlyakhto E. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic. Front Immunol Mini Rev. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1335424.","DOI":"10.3389\/fimmu.2024.1335424"},{"issue":"22","key":"415_CR27","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA. 2024;332(22):1924\u201335.","journal-title":"JAMA"},{"key":"415_CR28","volume-title":"Vivo CRISPR Knockout Screen","author":"T Kienka","year":"2024","unstructured":"Kienka T, Improving CART. Cell Persistence in Pancreatic Cancer Using an In Vivo CRISPR Knockout Screen. Harvard University; 2024."},{"key":"415_CR29","doi-asserted-by":"publisher","first-page":"116439","DOI":"10.1016\/j.bcp.2024.116439","volume":"227","author":"W Zhao","year":"2024","unstructured":"Zhao W, et al. Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy. Biochem Pharmacol. 2024;227:116439.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"415_CR30","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1002\/mef2.79","volume":"3","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Huang J, Xu Y, Luo HY. Current progress in chimeric antigen receptor T-cell therapy for malignant tumors. MedComm\u2013Future Med. 2024;3(2):e79.","journal-title":"MedComm\u2013Future Med"},{"key":"415_CR31","doi-asserted-by":"publisher","first-page":"100739","DOI":"10.1016\/j.iotech.2024.100739","volume":"24","author":"C Carcopino","year":"2024","unstructured":"Carcopino C, Erdogan E, Henrich M, Kobold S. Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy. Immuno-Oncology Technol. 2024;24:100739.","journal-title":"Immuno-Oncology Technol"},{"key":"415_CR32","doi-asserted-by":"publisher","first-page":"10938","DOI":"10.3389\/ebm.2026.10938","volume":"251","author":"P Vicenova","year":"2026","unstructured":"Vicenova P, Maher J. How can we balance risk and benefit of interleukin-18 armored T cell therapies? Experimental Biology Med. 2026;251:10938.","journal-title":"Experimental Biology Med"},{"issue":"1","key":"415_CR33","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1186\/s12967-024-05903-3","volume":"20","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. CAR-armored-cell therapy in solid tumor treatment. J translational Med. 2024;20(1):1076.","journal-title":"J translational Med"},{"key":"415_CR34","doi-asserted-by":"publisher","first-page":"1333150","DOI":"10.3389\/fimmu.2024.1333150","volume":"15","author":"P Ercilla-Rodriguez","year":"2024","unstructured":"Ercilla-Rodriguez P, et al. CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects. Front Immunol. 2024;15:1333150.","journal-title":"Front Immunol"},{"key":"415_CR35","doi-asserted-by":"publisher","unstructured":"Alsaieedi A, Zaher KA. Tracing the development of CAR-T cell design: from concept to next-generation platforms. Front Immunol Rev. 2025;16. https:\/\/doi.org\/10.3389\/fimmu.2025.1615212.","DOI":"10.3389\/fimmu.2025.1615212"},{"key":"415_CR36","doi-asserted-by":"publisher","first-page":"1407992","DOI":"10.3389\/fimmu.2024.1407992","volume":"15","author":"M Alviano","year":"2024","unstructured":"Alviano M, Biondi M, Grassenis E, Biondi A, Serafini M, Tettamanti S. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies. Front Immunol. 2024;15:1407992.","journal-title":"Front Immunol"},{"key":"415_CR37","doi-asserted-by":"publisher","unstructured":"Smith R. Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies. Front Immunol Rev. 2024:15. https:\/\/doi.org\/10.3389\/fimmu.2024.1490911.","DOI":"10.3389\/fimmu.2024.1490911"},{"issue":"1","key":"415_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","volume":"16","author":"M-L Schubert","year":"2026","unstructured":"Schubert M-L, et al Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J Hematol Oncol. 2026;16(1):79. https:\/\/doi.org\/10.1186\/s13045-023-01470-0.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"415_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Reviews Clin Oncol. 2024;21(1):47\u201366. https:\/\/doi.org\/10.1038\/s41571-023-00832-4.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"7949","key":"415_CR40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614(7949):635\u201348. https:\/\/doi.org\/10.1038\/s41586-023-05707-3.","journal-title":"Nature"},{"issue":"12","key":"415_CR41","first-page":"1385","volume":"141","author":"G Sotillo","year":"2023","unstructured":"Sotillo G, et al. Mechanisms of antigen escape in CAR-T cell therapy. Blood. 2023;141(12):1385\u201395.","journal-title":"Blood"},{"issue":"4","key":"415_CR42","first-page":"275","volume":"23","author":"JH Cho","year":"2024","unstructured":"Cho JH, Okuma A, Wong K. Logic-gated synthetic biology approaches for targeted cell therapies. Nat Rev Drug Discov. 2024;23(4):275-92.","journal-title":"Nat Rev Drug Discov"},{"issue":"7952","key":"415_CR43","first-page":"480","volume":"615","author":"RC Lynn","year":"2023","unstructured":"Lynn RC, et al. c-Jun overexpression overrides T cell exhaustion and enhances CAR-T cell potency. Nature. 2023;615(7952):480\u20138.","journal-title":"Nature"},{"issue":"1","key":"415_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, et al Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105. https:\/\/doi.org\/10.1186\/s13045-024-01625-7.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"415_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14737140.2024.2421194","volume":"25","author":"N Mobark","year":"2025","unstructured":"Mobark N, Hull CM, Maher J. Optimising CAR T therapy for the treatment of solid tumors. Expert Rev Anticancer Ther. 2025;25(1):9\u201325. https:\/\/doi.org\/10.1080\/14737140.2024.2421194","journal-title":"Expert Rev Anticancer Ther"},{"issue":"19","key":"415_CR46","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1158\/1078-0432.Ccr-23-3298","volume":"30","author":"LJ Talbot","year":"2024","unstructured":"Talbot LJ, et al Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models. Clin Cancer Res. 2024;30(19):4434\u201349. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-3298.","journal-title":"Clin Cancer Res"},{"key":"415_CR47","doi-asserted-by":"publisher","first-page":"103020","DOI":"10.1016\/j.copbio.2023.103020","volume":"84","author":"M Hong","year":"2023","unstructured":"Hong M, Talluri S, Chen YY Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors. Curr Opin Biotechnol. 2023;84:103020. https:\/\/doi.org\/10.1016\/j.copbio.2023.103020.","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"415_CR48","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/s2352-3026(24)00273-4","volume":"12","author":"G Agliardi","year":"2025","unstructured":"Agliardi G, Dias J, Rampotas A, Garcia J, Roddie C Accelerating and optimising CAR T-cell manufacture to deliver better patient products. (in eng) Lancet Haematol. 2025;12(1):e57\u201367. https:\/\/doi.org\/10.1016\/s2352-3026(24)00273-4.","journal-title":"(in eng) Lancet Haematol"},{"key":"415_CR49","doi-asserted-by":"publisher","unstructured":"Dias J, Garcia J, Agliardi G, Roddie C. CAR-T cell manufacturing landscape\u2014Lessons from the past decade and considerations for early clinical development. Mol Therapy Methods Clin Dev. 2024;32(2). https:\/\/doi.org\/10.1016\/j.omtm.2024.101250.","DOI":"10.1016\/j.omtm.2024.101250"},{"key":"415_CR50","doi-asserted-by":"publisher","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221(2). https:\/\/doi.org\/10.1084\/jem.20230903.","DOI":"10.1084\/jem.20230903"},{"key":"415_CR51","doi-asserted-by":"publisher","unstructured":"Herzberg, et al. Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin\u2019s lymphoma. (in eng) J Immunother Cancer. 2025;13(4). https:\/\/doi.org\/10.1136\/jitc-2024-010709.","DOI":"10.1136\/jitc-2024-010709"},{"issue":"3","key":"415_CR52","doi-asserted-by":"publisher","first-page":"101566","DOI":"10.1016\/j.beha.2024.101566","volume":"37","author":"S van den Chen","year":"2024","unstructured":"Chen S, van den Brink MRM Allogeneic Off-the-Shelf CAR T cells: Challenges and advances. Best Pract Res Clin Haematol. 2024;37(3):101566. https:\/\/doi.org\/10.1016\/j.beha.2024.101566.","journal-title":"Best Pract Res Clin Haematol"},{"key":"415_CR53","doi-asserted-by":"publisher","unstructured":"Barden M, et al. Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function. (in eng) J Immunother Cancer. 2024;12(12). https:\/\/doi.org\/10.1136\/jitc-2024-010208.","DOI":"10.1136\/jitc-2024-010208"},{"issue":"7","key":"415_CR54","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jcyt.2024.02.024","volume":"26","author":"MA Nix","year":"2024","unstructured":"Nix MA, Wiita AP Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments. Cytotherapy. 2024;26(7):729\u201338. https:\/\/doi.org\/10.1016\/j.jcyt.2024.02.024.","journal-title":"Cytotherapy"},{"issue":"1","key":"415_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41392-024-02096-5","volume":"10","author":"P Wang","year":"2025","unstructured":"Wang P, et al Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells. Signal Transduct Target Therapy. 2025;10(1):20. https:\/\/doi.org\/10.1038\/s41392-024-02096-5.","journal-title":"Signal Transduct Target Therapy"},{"issue":"12","key":"415_CR56","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","volume":"38","author":"T Lei","year":"2024","unstructured":"Lei T, et al Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024;38(12):2517\u201343. https:\/\/doi.org\/10.1038\/s41375-024-02444-y.","journal-title":"Leukemia"},{"key":"415_CR57","doi-asserted-by":"publisher","unstructured":"Rossi M, Breman E. Engineering strategies to safely drive CAR T-cells into the future, (in English). Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1411393.","DOI":"10.3389\/fimmu.2024.1411393"},{"issue":"8","key":"415_CR58","doi-asserted-by":"publisher","first-page":"2309088","DOI":"10.1002\/advs.202309088","volume":"11","author":"P Teixeira","year":"2024","unstructured":"Teixeira P, Fussenegger M Synthetic Gene Circuits for Regulation of Next-Generation Cell-Based Therapeutics. Adv Sci. 2024;11(8):2309088. https:\/\/doi.org\/10.1002\/advs.202309088.","journal-title":"Adv Sci"},{"key":"415_CR59","doi-asserted-by":"publisher","unstructured":"Partin C, et al. Geometric parameters that affect the behavior of logic-gated CAR T cells. (in English) Front Immunol Original Res. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1304765.","DOI":"10.3389\/fimmu.2024.1304765"},{"issue":"10","key":"415_CR60","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41422-023-00828-w","volume":"33","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Sadelain M CAR T cell design: approaching the elusive AND-gate. Cell Res. 2023;33(10):739\u201340. https:\/\/doi.org\/10.1038\/s41422-023-00828-w.","journal-title":"Cell Res"},{"issue":"5","key":"415_CR61","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/bjh.19348","volume":"204","author":"H Brillembourg","year":"2024","unstructured":"Brillembourg H, et al The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies. Br J Haematol. 2024;204(5):1649\u201359. https:\/\/doi.org\/10.1111\/bjh.19348.","journal-title":"Br J Haematol"},{"issue":"4","key":"415_CR62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","volume":"9","author":"G de Oliveira Canedo","year":"2025","unstructured":"de Oliveira Canedo G, Roddie C, Amrolia PJ Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. Blood Adv. 2025;9(4):704\u201321. https:\/\/doi.org\/10.1182\/bloodadvances.2024013586.","journal-title":"Blood Adv"},{"key":"415_CR63","doi-asserted-by":"publisher","unstructured":"Kong Y, Li J, Zhao X, Wu Y, Chen L. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. (in English) Front Immunol. 2025;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1519671.","DOI":"10.3389\/fimmu.2024.1519671"},{"issue":"5","key":"415_CR64","doi-asserted-by":"publisher","first-page":"C1473","DOI":"10.1152\/ajpcell.00659.2024","volume":"328","author":"L Song","year":"2025","unstructured":"Song L, Zhang Q, Sui H, Gao C, Jiang Z Recent advances in synthetic Notch receptors for biomedical application. Am J Physiology-Cell Physiol. 2025;328(5):C1473\u201386. https:\/\/doi.org\/10.1152\/ajpcell.00659.2024.","journal-title":"Am J Physiology-Cell Physiol"},{"issue":"1","key":"415_CR65","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/s41467-023-37863-5","volume":"14","author":"E Ruffo","year":"2023","unstructured":"Ruffo E, et al. Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting. Nat Commun. 2023;14(1):2463. https:\/\/doi.org\/10.1038\/s41467-023-37863-5.","journal-title":"Nat Commun"},{"issue":"6","key":"415_CR66","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/14712598.2024.2371034","volume":"24","author":"U Zajc","year":"2024","unstructured":"Zajc U Sylvander E, Lehner M, Traxlmayr MW. Small molecule-regulated switches to provide functional control of CAR T cells within the patient. Expert Opin Biol Ther. 2024;24(6):425\u201332. https:\/\/doi.org\/10.1080\/14712598.2024.2371034 ,","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"415_CR67","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40259-024-00688-9","volume":"39","author":"K Mestermann","year":"2025","unstructured":"Mestermann K, Garitano-Trojaola A, Hudecek M Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors. BioDrugs. 2025;39(1):33\u201351. https:\/\/doi.org\/10.1007\/s40259-024-00688-9.","journal-title":"BioDrugs"},{"issue":"2","key":"415_CR68","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","volume":"8","author":"C Baguet","year":"2024","unstructured":"Baguet C, Larghero J, Mebarki M Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies. Blood Adv. 2024;8(2):337\u201342. https:\/\/doi.org\/10.1182\/bloodadvances.2023011992.","journal-title":"Blood Adv"},{"key":"415_CR69","doi-asserted-by":"publisher","unstructured":"Mohty R, Lazaryan A. Off-The-Shelf allogeneic chimeric antigen receptor T-cell therapy for B-cell malignancies: current clinical evidence and challenges. (in English) Front Oncol Mini Rev. 2024;14. https:\/\/doi.org\/10.3389\/fonc.2024.1433432.","DOI":"10.3389\/fonc.2024.1433432"},{"issue":"1","key":"415_CR70","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z, et al Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 2024;14(1):213. https:\/\/doi.org\/10.1038\/s41408-024-01193-6.","journal-title":"Blood Cancer J"},{"issue":"1","key":"415_CR71","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","volume":"22","author":"DT Diorio","year":"2025","unstructured":"Diorio DT, Teachey, Grupp SA Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. Nat Reviews Clin Oncol. 2025;22(1):10\u201327. https:\/\/doi.org\/10.1038\/s41571-024-00959-y.","journal-title":"Nat Reviews Clin Oncol"},{"key":"415_CR72","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-cancerbio-062822-023316","volume":"8","author":"J Sasu","year":"2024","unstructured":"Sasu J, Lauron EJ, Schulz T, Cheng H-Y, Sommer C Allogeneic CAR T Cell Therapy for Cancer. Annual Rev Cancer Biology. 2024;8:227\u201343. https:\/\/doi.org\/10.1146\/annurev-cancerbio-062822-023316.","journal-title":"Annual Rev Cancer Biology"},{"issue":"1","key":"415_CR73","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","volume":"24","author":"S Mansoori","year":"2024","unstructured":"Mansoori S, Noei A, Maali A, Seyed-Motahari SS, Sharifzadeh Z. Recent updates on allogeneic CAR-T cells in hematological malignancies. Cancer Cell International. 2024;24(1):304. https:\/\/doi.org\/10.1186\/s12935-024-03479-y.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"415_CR74","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/cells13020146","volume":"13","author":"E Lonez","year":"2024","unstructured":"Lonez and E. Breman, \u201cAllogeneic CAR-T Therapy Technologies: Has the Promise Been Met?,\u201d Cells, vol. 13, no. 2, p. 146, 2024. [. Available:","journal-title":"Cells"},{"issue":"9","key":"415_CR75","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-024-01022-8","volume":"24","author":"KE Martin","year":"2024","unstructured":"Martin KE, Hammer Q, Perica K, Sadelain M, Malmberg K-J Engineering immune-evasive allogeneic cellular immunotherapies. Nat Rev Immunol. 2024;24(9):680\u201393. https:\/\/doi.org\/10.1038\/s41577-024-01022-8.","journal-title":"Nat Rev Immunol"},{"key":"415_CR76","doi-asserted-by":"publisher","unstructured":"Chen X et al Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies, (in eng), Cancer Immunol Immunother. 2024;73(1):13. https:\/\/doi.org\/10.1007\/s00262-023-03586-1.","DOI":"10.1007\/s00262-023-03586-1"},{"issue":"8","key":"415_CR77","first-page":"100677","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Zhu Y, Fang Y, Lyu Z, Yang L. Emerging trends in clinical allogeneic CAR cell therapy.Med. 2025;6(8):100677.","journal-title":"(in eng) Med"},{"issue":"6","key":"415_CR78","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1016\/j.ymthe.2024.11.035","volume":"33","author":"YR Li","year":"2025","unstructured":"Li YR, Fang Y, Niu S, Chen Y, Lyu Z, Yang L Managing allorejection in off-the-shelf CAR-engineered cell therapies. (in eng) Mol Ther. 2025;33(6):2368\u201390. https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.035.","journal-title":"(in eng) Mol Ther"},{"key":"415_CR79","doi-asserted-by":"publisher","unstructured":"Kim H. Overcoming Immune Barriers in Allogeneic CAR-NK Therapy: From Multiplex Gene Editing to AI-Driven Precision Design. (in eng) Biomolecules. 2025;15(7). https:\/\/doi.org\/10.3390\/biom15070935","DOI":"10.3390\/biom15070935"},{"key":"415_CR80","doi-asserted-by":"publisher","unstructured":"Mohammad, et al Modular (universal) CAR-T platforms in vivo: a comprehensive systematic review. (in English) Front Immunol Syst Rev. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1409665.","DOI":"10.3389\/fimmu.2024.1409665"},{"key":"415_CR81","doi-asserted-by":"publisher","unstructured":"Schlegel LS, Werbrouck C, Boettcher M, Schlegel P Universal CAR 2.0 to overcome current limitations in CAR therapy. (in English) Front Immunol Rev. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1383894.","DOI":"10.3389\/fimmu.2024.1383894"},{"key":"415_CR82","doi-asserted-by":"publisher","unstructured":"Alidadi M, et al. Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects. Frontiers in Cell and Developmental Biology. 2024;18. https:\/\/doi.org\/10.3389\/fcell.2024.1491282.","DOI":"10.3389\/fcell.2024.1491282"},{"key":"415_CR83","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3390\/cells13181516","volume":"13","author":"HK Mishra","year":"2024","unstructured":"Mishra HK, Kalyuzhny A Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology, Cells. 2024;13(18):1516. Available:. https:\/\/www.mdpi.com\/2073-4409\/13\/18\/1516.","journal-title":"Cells"},{"key":"415_CR84","doi-asserted-by":"publisher","unstructured":"Li T, Niu M, Zhang W, Qin S, Zhou J, Yi M CAR-NK cells for cancer immunotherapy: recent advances and future directions. (in English) Front Immunol Mini Rev. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1361194.","DOI":"10.3389\/fimmu.2024.1361194"},{"key":"415_CR85","doi-asserted-by":"publisher","unstructured":"Kong J.C. et al.,Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges. Frontiers in Immunology.2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1384039.","DOI":"10.3389\/fimmu.2024.1384039"},{"key":"415_CR86","doi-asserted-by":"publisher","unstructured":"Huang T, Bei C, Hu Z, Li Y CAR-macrophage: Breaking new ground in cellular immunotherapy. (in English) Front Cell Dev Biology Rev. 2024;12. https:\/\/doi.org\/10.3389\/fcell.2024.1464218.","DOI":"10.3389\/fcell.2024.1464218"},{"key":"415_CR87","doi-asserted-by":"publisher","unstructured":"Andrea E, Chiron A, Sarrabayrouse G, Bessoles S, Hacein-Bey-Abina S A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors? (in English) Front Immunol Rev. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1459818.","DOI":"10.3389\/fimmu.2024.1459818"},{"key":"415_CR88","doi-asserted-by":"publisher","first-page":"102147","DOI":"10.1016\/j.tranon.2024.102147","volume":"51","author":"Z Wu","year":"2025","unstructured":"Wu Z, Wang Y, Jin X, Wang L Universal CAR cell therapy: Challenges and expanding applications. Translational Oncol. 2025;51:102147. https:\/\/doi.org\/10.1016\/j.tranon.2024.102147.","journal-title":"Translational Oncol"},{"issue":"1","key":"415_CR89","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C-x, Zhu Z CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Experimental Clin Cancer Res. 2022;41(1):119. https:\/\/doi.org\/10.1186\/s13046-022-02327-z.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"1","key":"415_CR90","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16(1):97. https:\/\/doi.org\/10.1186\/s13045-023-01492-8.","journal-title":"J Hematol Oncol"},{"key":"415_CR91","doi-asserted-by":"publisher","first-page":"1675807","DOI":"10.3389\/fimmu.2025.1675807","volume":"16","author":"Y Hou","year":"2025","unstructured":"Hou Y, et al Beyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-\u03b3\u03b4 T strategies in solid tumor immunotherapy. (in eng) Front Immunol. 2025;16:1675807. https:\/\/doi.org\/10.3389\/fimmu.2025.1675807.","journal-title":"(in eng) Front Immunol"},{"issue":"1","key":"415_CR92","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","volume":"43","author":"Y-R Li","year":"2025","unstructured":"Li Y-R et al., Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nature biotechnology. 2025;43(3):329\u2013344. https:\/\/doi.org\/10.1038\/s41587-024-02226-y.","journal-title":"Nat Biotechnol"},{"key":"415_CR93","doi-asserted-by":"publisher","unstructured":"Li Y-R et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med.2025;6(10). https:\/\/doi.org\/10.1016\/j.medj.2025.100804.","DOI":"10.1016\/j.medj.2025.100804"},{"issue":"1","key":"415_CR94","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41467-025-56270-6","volume":"16","author":"YR Li","year":"2025","unstructured":"Li YR, et al Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. (in eng) Nat Commun. 2025;16(1):1248. https:\/\/doi.org\/10.1038\/s41467-025-56270-6.","journal-title":"(in eng) Nat Commun"},{"issue":"1","key":"415_CR95","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-025-01736-9","volume":"18","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, et al. Targeting triple-negative breast cancer using cord-blood CD34\u207a HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025;18(1):86.","journal-title":"J Hematol Oncol"},{"key":"415_CR96","doi-asserted-by":"publisher","first-page":"1675807","DOI":"10.3389\/fimmu.2025.1675807","volume":"16","author":"Y Hou","year":"2025","unstructured":"Hou Y, et al. Beyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-\u03b3\u03b4 T strategies in solid tumor immunotherapy. Front Immunol. 2025;16:1675807.","journal-title":"Front Immunol"},{"issue":"12","key":"415_CR97","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"14","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Posey AD Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;14(12):1994\u20132007. https:\/\/doi.org\/10.1038\/s41590-023-01659-y.","journal-title":"Nat Immunol"},{"key":"415_CR98","doi-asserted-by":"publisher","unstructured":"Nguyen NTT, et al The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity. (in eng) Cancers (Basel). 2024;16(14). https:\/\/doi.org\/10.3390\/cancers16142608.","DOI":"10.3390\/cancers16142608"},{"issue":"1","key":"415_CR99","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40164-024-00583-7","volume":"13","author":"P Yao","year":"2024","unstructured":"Yao P, Liu Y-G, Huang G, Hao L, Wang R The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances. Experimental Hematol Oncol. 2024;13(1):118. https:\/\/doi.org\/10.1186\/s40164-024-00583-7.","journal-title":"Experimental Hematol Oncol"},{"key":"415_CR100","doi-asserted-by":"publisher","unstructured":"Moradi V, Khodabandehloo E, Alidadi M, Omidkhoda A, Ahmadbeigi N Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review. (in English) Front Oncol Rev. 2024;17. https:\/\/doi.org\/10.3389\/fonc.2024.1388475.","DOI":"10.3389\/fonc.2024.1388475"},{"key":"415_CR101","doi-asserted-by":"publisher","unstructured":"Cappabianca, et al Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells, (in English), Frontiers in Bioengineering and Biotechnology. Original Res. 2024;12. https:\/\/doi.org\/10.3389\/fbioe.2024.1379900.","DOI":"10.3389\/fbioe.2024.1379900"},{"key":"415_CR102","doi-asserted-by":"publisher","unstructured":"Amiri M, Moaveni AK, Majidi Zolbin M, Shademan B, Nourazarian A Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR\/Cas9, (in English), Frontiers in Immunology, Review. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1462697.","DOI":"10.3389\/fimmu.2024.1462697"},{"issue":"6","key":"415_CR103","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","volume":"42","author":"M Fiumara","year":"2024","unstructured":"Fiumara M, et al. Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat Biotechnol. 2024;42(6):877\u201391.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"415_CR104","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41587-020-0414-6","volume":"38","author":"JL Doman","year":"2020","unstructured":"Doman JL, Raguram A, Newby GA, Liu DR. Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat Biotechnol. 2020;38(5):620\u20138.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"415_CR105","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41434-024-00499-1","volume":"32","author":"JB Murray","year":"2025","unstructured":"Murray JB, Harrison PT, Scholefield J. Prime editing: therapeutic advances and mechanistic insights. Gene Ther. 2025;32(2):83\u201392. https:\/\/doi.org\/10.1038\/s41434-024-00499-1","journal-title":"Gene Ther"},{"issue":"12","key":"415_CR106","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41571-025-01072-4","volume":"22","author":"1K Petri","year":"2025","unstructured":"Petri K et al., Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities. Nat Rev Clin Oncol. 2025;22(12):902\u2013923. https:\/\/doi.org\/10.1038\/s41571-025-01072-4.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"415_CR107","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.hlife.2024.06.002","volume":"2","author":"L Yan","year":"2024","unstructured":"Yan L, Gao S, Wang X, Zhou X, Limsakul P, Wu Y Boosting CAR-T cell therapy with CRISPR technology. hLife. 2024;2(8):380\u201396. https:\/\/doi.org\/10.1016\/j.hlife.2024.06.002.","journal-title":"hLife"},{"issue":"8","key":"415_CR108","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41587-024-02320-1","volume":"42","author":"SR McCutcheon","year":"2024","unstructured":"McCutcheon SR, Rohm D, Iglesias N, Gersbach CA Epigenome editing technologies for discovery and medicine. Nat Biotechnol. 2024;42(8):1199\u2013217. https:\/\/doi.org\/10.1038\/s41587-024-02320-1.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"415_CR109","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40364-024-00602-z","volume":"12","author":"P Song","year":"2024","unstructured":"Song P, Zhang Q, Xu Z, Shi Y, Jing R, Luo D CRISPR\/Cas-based CAR-T cells: production and application. Biomark Res. 2024;12(1):54. https:\/\/doi.org\/10.1186\/s40364-024-00602-z.","journal-title":"Biomark Res"},{"key":"415_CR110","doi-asserted-by":"publisher","first-page":"122683","DOI":"10.1016\/j.lfs.2024.122683","volume":"348","author":"Y Metanat","year":"2024","unstructured":"Metanat Y, et al The paths toward non-viral CAR-T cell manufacturing: A comprehensive review of state-of-the-art methods. Life Sci. 2024;348:122683. https:\/\/doi.org\/10.1016\/j.lfs.2024.122683.","journal-title":"Life Sci"},{"key":"415_CR111","doi-asserted-by":"publisher","first-page":"13685","DOI":"10.3390\/ijms252413685","volume":"24","author":"L Gehrke","year":"2024","unstructured":"Gehrke L et al Current Non-Viral-Based Strategies to Manufacture CAR-T Cells, International Journal of Molecular Sciences. 2024;25(24):13685. Available: https:\/\/www.mdpi.com\/1422-0067\/25\/24\/13685.","journal-title":"International Journal of Molecular Sciences"},{"issue":"12","key":"415_CR112","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41551-024-01219-1","volume":"8","author":"W-X Sin","year":"2024","unstructured":"Sin W-X, et al A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells. Nat Biomedical Eng. 2024;8(12):1571\u201391. https:\/\/doi.org\/10.1038\/s41551-024-01219-1.","journal-title":"Nat Biomedical Eng"},{"issue":"5","key":"415_CR113","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short L, Holt RA, Cullis PR, Evgin L. Direct in vivo CAR T cell engineering. Trends Pharmacol Sci. 2024;45(5):406\u2013418. https:\/\/doi.org\/10.1016\/j.tips.2024.03.004","journal-title":"Trends Pharmacol Sci"},{"issue":"6576","key":"415_CR114","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u20136.https:\/\/doi.org\/10.1126\/science.abm0594","journal-title":"Science"},{"issue":"1","key":"415_CR115","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","volume":"23","author":"Pinto","year":"2025","unstructured":"Pinto, et al From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. J Translational Med. 2025;23(1):10. https:\/\/doi.org\/10.1186\/s12967-024-06052-3.","journal-title":"J Translational Med"},{"issue":"7","key":"415_CR116","doi-asserted-by":"publisher","first-page":"e011759","DOI":"10.1136\/jitc-2025-011759","volume":"13","author":"JF Bimbo","year":"2025","unstructured":"Bimbo JF, et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. J Immunother Cancer. 2025;13(7):e011759.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"415_CR117","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","volume":"25","author":"YR Li","year":"2025","unstructured":"Li YR, Zhu Y, Halladay T, Yang L In vivo CAR engineering for immunotherapy. (in eng) Nat Rev Immunol. 2025;25(10):725\u201344. https:\/\/doi.org\/10.1038\/s41577-025-01174-1.","journal-title":"(in eng) Nat Rev Immunol"},{"key":"415_CR118","doi-asserted-by":"publisher","first-page":"1165576","DOI":"10.3389\/fimmu.2023.1165576","volume":"14","author":"Y-T Qin","year":"2023","unstructured":"Qin Y-T, Li Y-P, He X-W, Wang X, Li W-Y, Zhang Y-K. Biomaterials promote in vivo generation and immunotherapy of CAR-T cells. Front Immunol. 2023;14:1165576.","journal-title":"Front Immunol"},{"issue":"1","key":"415_CR119","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tips.2025.11.001","volume":"47","author":"YR Li","year":"2026","unstructured":"Li YR, Yang L Autologous, allogeneic, in vivo CAR for autoimmune diseases. (in eng) Trends Pharmacol Sci. 2026;47(1):11\u20134. https:\/\/doi.org\/10.1016\/j.tips.2025.11.001.","journal-title":"(in eng) Trends Pharmacol Sci"},{"issue":"1","key":"415_CR120","doi-asserted-by":"publisher","first-page":"100027","DOI":"10.1016\/j.bict.2025.100027","volume":"2","author":"L Volta","year":"2026","unstructured":"Volta L, Gill SI. In vivo generation of CAR T cells: biology, delivery platforms, clinical promise, and translational challenges. Blood Immunol Cell Therapy. 2026;2(1):100027.","journal-title":"Blood Immunol Cell Therapy"},{"issue":"11","key":"415_CR121","doi-asserted-by":"publisher","first-page":"e2304378","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, et al In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism. (in eng) Small. 2024;20(11):e2304378. https:\/\/doi.org\/10.1002\/smll.202304378.","journal-title":"(in eng) Small"},{"issue":"9","key":"415_CR122","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/14712598.2024.2399141","volume":"24","author":"Klampatsa","year":"2024","unstructured":"Klampatsa. Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors. Expert Opin Biol Ther. 2024;24(9):879\u201381. . (in eng). https:\/\/doi.org\/10.1080\/14712598.2024.2399141.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"415_CR123","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41571-023-00729-2","volume":"20","author":"J Yang","year":"2023","unstructured":"Yang J, Chen Y, Jing Y, Green MR, Han L Advancing CAR T cell therapy through the use of multidimensional omics data. Nat Reviews Clin Oncol. 2023;20(4):211\u201328. https:\/\/doi.org\/10.1038\/s41571-023-00729-2.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"7","key":"415_CR124","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1158\/2326-6066.Cir-23-0699","volume":"12","author":"G Di Mauro","year":"2024","unstructured":"Di Mauro, Arbore G Spatial Dissection of the Immune Landscape of Solid Tumors to Advance Precision Medicine. Cancer Immunol Res. 2024;12(7):800\u201313. https:\/\/doi.org\/10.1158\/2326-6066.Cir-23-0699.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"415_CR125","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen T, Wang M, Chen Y, Liu Y Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 2024;24(1):133. https:\/\/doi.org\/10.1186\/s12935-024-03315-3.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"415_CR126","first-page":"1381","volume":"6","author":"F-E Mustaffa","year":"2026","unstructured":"Mustaffa F-E, Irshad S, Sajid T, Gillani SM, Saeed N, Adan N Stem cells and cancer: recent updates in tumor biology, cancer stem cells, and targeted therapies, Journal of Current Oncology and Medical Sciences. 2026;6(1):1381\u20131400. Available:. https:\/\/submission.journalofcoms.com\/index.php\/JCOMS\/article\/view\/466.","journal-title":"Journal of Current Oncology and Medical Sciences"},{"issue":"7","key":"415_CR127","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"J Hou","year":"2021","unstructured":"Hou J, Chen LC, Chen YY Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discovery. 2021;20(7):531\u201350. https:\/\/doi.org\/10.1038\/s41573-021-00189-2.","journal-title":"Nat Rev Drug Discovery"},{"issue":"10494","key":"415_CR128","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/s0140-6736(25)00860-8","volume":"405","author":"Qi","year":"2025","unstructured":"Qi, et al Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. (in eng) Lancet. 2025;405(10494):2049\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(25)00860-8.","journal-title":"(in eng) Lancet"},{"issue":"1","key":"415_CR129","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","volume":"6","author":"Fandrei","year":"2025","unstructured":"Fandrei, et al. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma. Blood cancer discovery. 2025;6(1):38\u201354.","journal-title":"Blood cancer discovery"},{"issue":"10","key":"415_CR130","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.3324\/haematol.2024.285255","volume":"109","author":"M Melody","year":"2024","unstructured":"Melody M, Gordon LI. Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma. Haematologica. 2024;109(10):3138.","journal-title":"Haematologica"},{"key":"415_CR131","doi-asserted-by":"publisher","first-page":"1455163","DOI":"10.3389\/fimmu.2024.1455163","volume":"20224","author":"TL Ponterio","year":"2024","unstructured":"Ponterio TL, Haas, De Maria R Oncolytic virus and CAR-T cell therapy in solid tumors. (in eng) Front Immunol. 2024;15:1455163. https:\/\/doi.org\/10.3389\/fimmu.2024.1455163.","journal-title":"(in eng) Front Immunol"},{"key":"415_CR132","doi-asserted-by":"publisher","unstructured":"Stilpeanu RI, Secara BS, Cretu-Stancu M, Bucur O Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors. (in eng) Int J Mol Sci. 2024;25(20). https:\/\/doi.org\/10.3390\/ijms252011127.","DOI":"10.3390\/ijms252011127"},{"key":"415_CR133","doi-asserted-by":"publisher","unstructured":"Zhong L, Li Y, Muluh TA, Wang Y Combination of CAR\u2013T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review), (in eng), Oncol Lett. 2023;26(1):281. https:\/\/doi.org\/10.3892\/ol.2023.13867.","DOI":"10.3892\/ol.2023.13867"},{"issue":"5","key":"415_CR134","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini L, et al Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Reviews Clin Oncol. 2022;19(5):342\u201355. https:\/\/doi.org\/10.1038\/s41571-022-00607-3.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"415_CR135","doi-asserted-by":"publisher","first-page":"2412876","DOI":"10.1080\/2162402x.2024.2412876","volume":"12","author":"Borges","year":"2024","unstructured":"Borges, et al Trial watch: anticancer vaccination with dendritic cells. (in eng) Oncoimmunology. 2024;12(1):2412876. https:\/\/doi.org\/10.1080\/2162402x.2024.2412876.","journal-title":"(in eng) Oncoimmunology"},{"issue":"5","key":"415_CR136","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s44222-023-00148-z","volume":"2","author":"N Eckman","year":"2024","unstructured":"Eckman N, Nejatfard A, Cavet R, Grosskopf AK, Appel EA Biomaterials to enhance adoptive cell therapy. Nat Reviews Bioeng. 2024;2(5):408\u201324. https:\/\/doi.org\/10.1038\/s44222-023-00148-z.","journal-title":"Nat Reviews Bioeng"},{"key":"415_CR137","doi-asserted-by":"publisher","unstructured":"Zhang PF, Xie D Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope? (in eng), Front Immunol. 2024;15:1362133. https:\/\/doi.org\/10.3389\/fimmu.2024.1362133.","DOI":"10.3389\/fimmu.2024.1362133"},{"issue":"10","key":"415_CR138","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41551-025-01492-8","volume":"9","author":"TT Nguyen","year":"2025","unstructured":"Nguyen TT, et al Fine tuning towards the next generation of engineered T cells. Nat Biomedical Eng. 2025;9(10):1610\u201331. https:\/\/doi.org\/10.1038\/s41551-025-01492-8.","journal-title":"Nat Biomedical Eng"},{"issue":"7","key":"415_CR139","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN Current understanding and management of CAR T cell-associated toxicities. Nat Reviews Clin Oncol. 2024;21(7):501\u201321. https:\/\/doi.org\/10.1038\/s41571-024-00903-0.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"7","key":"415_CR140","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN Current understanding and management of CAR T cell-associated toxicities. (in eng) Nat Rev Clin Oncol. 2024;21(7):501\u201321. https:\/\/doi.org\/10.1038\/s41571-024-00903-0.","journal-title":"(in eng) Nat Rev Clin Oncol"},{"key":"415_CR141","doi-asserted-by":"publisher","first-page":"1739021","DOI":"10.3389\/fneur.2026.1739021","volume":"17","author":"A Aziz","year":"2026","unstructured":"Aziz A, Chakraborty D, Saha, Dutta P Immune effector cell-associated neurotoxicity syndrome: integrative mechanisms, predictive biomarkers, and translational pathways for prevention in CAR T-cell therapy. (in eng) Front Neurol. 2026;17:1739021. https:\/\/doi.org\/10.3389\/fneur.2026.1739021.","journal-title":"(in eng) Front Neurol"},{"key":"415_CR142","doi-asserted-by":"publisher","unstructured":"Levstek L, Jan\u017ei\u010d L, Ihan A, Kopitar AN Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives. (in English) Front Immunol Rev. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1378944.","DOI":"10.3389\/fimmu.2024.1378944"},{"issue":"6","key":"415_CR143","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/s2352-3026(24)00077-2","volume":"11","author":"K Rejeski","year":"2024","unstructured":"Rejeski K, Jain MD, Shah NN, Perales MA, Subklewe M Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. (in eng) Lancet Haematol. 2024;11(6):e459\u201370. https:\/\/doi.org\/10.1016\/s2352-3026(24)00077-2.","journal-title":"(in eng) Lancet Haematol"},{"key":"415_CR144","doi-asserted-by":"publisher","unstructured":"Ercilla-Rodr\u00edguez P, et al CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects. (in English) Front Immunol Rev. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1333150.","DOI":"10.3389\/fimmu.2024.1333150"},{"key":"415_CR145","doi-asserted-by":"publisher","unstructured":"Garcia-Robledo JE, et al Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance. (in English) Front Oncol Rev. 2026;15. https:\/\/doi.org\/10.3389\/fonc.2025.1698442.","DOI":"10.3389\/fonc.2025.1698442"},{"key":"415_CR146","doi-asserted-by":"publisher","first-page":"1378944","DOI":"10.3389\/fimmu.2024.1378944","volume":"15","author":"L Levstek","year":"2024","unstructured":"Levstek L, Jan\u017ei\u010d L, Ihan A, Kopitar AN Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives. (in eng) Front Immunol. 2024;15:1378944. https:\/\/doi.org\/10.3389\/fimmu.2024.1378944.","journal-title":"(in eng) Front Immunol"},{"key":"415_CR147","doi-asserted-by":"publisher","unstructured":"AlMuhanna MH et al. Regenerative Therapy. https:\/\/doi.org\/10.1016\/j.reth.2026.101168.","DOI":"10.1016\/j.reth.2026.101168"},{"key":"415_CR148","doi-asserted-by":"publisher","unstructured":"Sepodes B, Burgos JG, Thirstrup S. European Medicines Agency approvals of new medicines in November and December 2025. Lancet Reg Health\u2013Europe. 2026;61. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101582.","DOI":"10.1016\/j.lanepe.2025.101582"},{"key":"415_CR149","doi-asserted-by":"publisher","first-page":"1557157","DOI":"10.3389\/fimmu.2025.1557157","volume":"16","author":"M Shokati","year":"2025","unstructured":"Shokati M, Sanjari-Pour M, Akhavan Rahnama S, Hoseinzadeh M, Vaezi, Ahmadvand M. Allogeneic CART progress: platforms, current progress and limitations. Front Immunol. 2025;16:1557157.","journal-title":"Front Immunol"},{"key":"415_CR150","doi-asserted-by":"publisher","unstructured":"Ogbogu U. Closing the gap? China\u2019s new regulation on biomedical technologies. Stem Cell Rep. 2026;21(7). https:\/\/doi.org\/10.1016\/j.stemcr.2026.102978.","DOI":"10.1016\/j.stemcr.2026.102978"},{"key":"415_CR151","doi-asserted-by":"publisher","unstructured":"Palani K et al. Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial. Mol Therapy Oncol. 2025;33(2). https:\/\/doi.org\/10.1016\/j.omton.2025.200977.","DOI":"10.1016\/j.omton.2025.200977"},{"issue":"23","key":"415_CR152","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1182\/bloodadvances.2024012982","volume":"8","author":"NN Urbano-Ispizua","year":"2024","unstructured":"\u00c1, Urbano-Ispizua NN, Shah, Kekre N. Point-of-care CAR T manufacturing solutions: can 1 model fit all? Blood Adv. 2024;8(23):6133\u20136.","journal-title":"Blood Adv"},{"key":"415_CR153","doi-asserted-by":"publisher","unstructured":"Ruiz, E. Shinabargar, I. Slovenski, K. Large, M. Vieira, and S. Moon, \u201cIncreasing access to CAR-T therapy: a case study of an academic hospital\u2019s alternative innovation model,\u201d Orphanet Journal of Rare Diseases, 2026. https:\/\/doi.org\/10.1186\/s13023-026-04320-7.","DOI":"10.1186\/s13023-026-04320-7"},{"issue":"18","key":"415_CR154","first-page":"2737","volume":"139","author":"LH Westin","year":"2022","unstructured":"Westin, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood J Am Soc Hematol. 2022;139(18):2737\u201346.","journal-title":"Blood J Am Soc Hematol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00415-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00415-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00415-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:05:11Z","timestamp":1790712311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00415-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":154,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00415-1","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"11 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is a narrative review synthesizing published literature. It does not involve studies with human participants, animals, or plants performed by the authors. Therefore, ethical approval and informed consent are not applicable. All authors affirm that the manuscript complies with the ethical standards of scholarly publishing, including integrity, transparency, and avoidance of plagiarism, data fabrication, or inappropriate citation practices.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"76"}}